Abstract:The cellular defect responsible for the cystic fibrosis (CF) syndrome has eluded precise description, although a flurry of reports over the past 6-7 years has identified the cell sites and the general nature of the dysfunction. Most likely, structural abnormalities of a membrane-associated regulatory protein' result in an inability to upregulate chloride channels and down-regulate sodium channels in the apical membranes of epithelial cells including those of conducting airways. * The postulated consequence in the lung is a net movement of salt and water from surface liquids into airway tissues, making mucous secretions salt deficient, relatively dehydrated, and refractory to clearance by ciliary mechanisms or cough.3 Intracellular regulation of ion translocation involves protein kinase A, protein kinase C, and intracellular calcium. The first two are ineffective modulators in CF epithelial cells ,4-8 but elevation of intracellular calcium does appear to open chloride channels in CF cells. With this information in hand, it is not surprising that thoughts are turning to the identification of more specific pharmacologic interventions for CF patients. Anbar and associates' in this issue cite previous work indicating that lithium may affect calcium metabolism" and the function of G proteins,'' several of which are involved with cation-channel regulation. l 2 They speculated that lithium might effect beneficial changes in CF epithelial function and undertook a double-blind, placebo-controlled trial of this drug in older CF patients. While such investigative approaches are to be encouraged, a more usual sequence of scientific inquiry would have been to first test the effect of lithium on ion translocation in cultured CF epithelial cells, thereby developing a stronger rationale for the clinical study. Had this been done, a rather extensive clinical trial that placed patients at some risk of adverse reactions and that had a largely negative outcome might not have been initiated. On the other hand, under these circumstances the authors would not have contributed the observation that lithium may be a risky drug for individuals with CF. This observation is likely to be a practical one, in that as the CF population ages, more and more patients with bipolar disorders needing lithium treatment are likely to be encountered. The observation by Anbar and colleagues that concentrations of chloride in sweat diminish during lithium treatment of individuals with CF is eye catching, but at second glance is neither physiologically impressive nor clearly indicative of a lithium effect on ion translocation mechanisms in sweat duct cells. Lithium could have achieved this effect by, for example, altering the rate of sweat production, a factor known to influence its chloride concentrations. l3 Furthermore, the importance of a small decrease in mean sweat chloride concentrations between preand post-treatment samples in this study is obscured by the recognition that 6 of 18 CF sweat chloride values were unchanged or increased after lithium administration. Although more than twice the number of hospitalizations were required for lithium-treated patients during and within 19 weeks after its administration, it is not certain that this effect was entirely attributable to declining pulmonary function. One complicating factor is that the two groups of subjects were not comparable on entry into the study. Patients to be treated with lithium had better mean FVC and FEV, values by more than 10% and 20%, respectively. Furthermore the small declines in these parameters were maximal at 4 weeks of lithium treatment, and by 10 weeks mean values had moved closer to entry levels. Thus, it is not clear that the increased need for hospitalization was entirely attributable to lithium-induced deterioration of lung function. Perhaps comparisons of mid-maximal expiratory flows, which would have been less effort-dependent and more sensitive to obstruction in small airways, would have provided a better assessment of airway dysfunction attributable to lithium. What can we learn from this study? Obviously, caution must be exercised in the treatment of CF patients with lithium. In addition, the possibility that lithium alters transport function of both sweat gland and airway epithelia in CF deserves careful investigation. A note of caution also may be in order. At a time when CF clinical research appears to be entering a most active and potentially productive phase, patient enrollment should be reserved for trials that have a sound scientific rationale and are most likely to provide important information. To do

COL4A3 mutations cause focal segmental glomerulosclerosis

A Pedigree with COL4A5 Mutation Presenting with Alport Syndrome and Focal Segmental Glomerulosclerosis Lesions: a Case Report.

Mutation analysis of COL4A3/COL4A4 genes in a family with thin basement membrane nephropathy and focal segmental glomerulosclerosis

A Novel Mutation of COL4A3 Presents a Different Contribution to Alport Syndrome and Thin Basement Membrane Nephropathy

Lithium, clinical research, and cystic fibrosis

Novel Mutations In Col4a3, Col4a4, And Col4a5 In Chinese Patients With Alport Syndrome

Genotype-phenotype correlations in 17 Chinese patients with autosomal recessive Alport syndrome.

Effect of Heterozygous Pathogenic COL4A3 or COL4A4 Variants on Patients with X-linked Alport Syndrome.

Case Report and Literature Review: A De Novo Pathogenic Missense Variant in ACTN4 Gene Caused Rapid Progression to End-Stage Renal Disease

Synergistic Toxicity of Compound Heterozygous Mutations in the COL4A3 Gene Causes End-Stage Renal Disease in A Large Family of Alport Syndrome

Anterior lumbar interbody fusion for the management of chronic lower back pain: current strategies and concepts.

Case report: A novel compound heterozygous variant in the COL4A3 gene was identified in a patient with autosomal recessive Alport syndrome

Genetic diagnosis of Alport syndrome in 16 Chinese families

A novel COL4A5 splicing mutation causes alport syndrome in a Chinese family

[Features of Clinical Phenotype and Genotype in Alport Syndrome: a Monocentric Study].

A Novel COL4A5 Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease

A Novel COL4A5 Splicing Mutation Causes Skipping of Exon 14 in a Chinese Family with Alport Syndrome

Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome

Identification of a Novel COL4A5 Mutation in the Proband Initially Diagnosed As IgAN from a Chinese Family with X-linked Alport Syndrome.

The First COL4A5 Exon 41A Glycine Substitution in a Family with Alport Syndrome

Novel Pathogenic Mutation of P209L in TRPC6 Gene Causes Adult Focal Segmental Glomerulosclerosis